Johns Hopkins' role in building experimental Ebola treatment ZMapp - Technical.ly Baltimore

Business

Dec. 16, 2014 8:57 am

Johns Hopkins’ role in building experimental Ebola treatment ZMapp

The scientists who created ZMapp previously worked in the lab of a JHU biophysicist.

Extracting antibodies from a Nicotiana benthamiana tobacco plant.

(Photo via Wikimedia Commons)

As Ebola rages through West Africa, Baltimore-based University of Maryland School of Medicine and Profectus Biosciences have each had their respective roles in speeding vaccines that could help curb the epidemic.

Last week, Johns Hopkins University touted its role in developing previously-elusive Ebola treatments, too.

ZMapp, which became the first much-talked-about Ebola treatment in August, has roots at the lab of Hopkins biophysicist Richard Cone, according to the JHU Hub. Mapp Biopharmaceutical’s Larry Zeitlin and Kevin Whaley, left JHU to form startups in California in 1999, and founded their current company in 2003. They said were inspired by Cone’s motivation to tackle “big public health problems.”

"ZMapp is not really the story. The real story is about antibodies and how diverse they are."
Kevin Whaley, Mapp Biopharmaceutical

ZMapp was developed by manufacturing antibodies from tobacco plants. Plantibodies, as experimental drugs like ZMapp are known, still largely haven’t received regulatory approval. Its effect on Ebola patients isn’t entirely known. Two U.S. pateints who were given the drug over the summer ultimately survived the disease, but a Maryland surgeon who was treated with ZMapp last month did not survive. Nevertheless, the U.S. government has asked labs to prepare to manufacture the drug as they seek to curb Ebola.

ZMapp vaulted Mapp Biopharmaceutical from obscurity. Its founders are hoping it will do the same for plantibodies.

“ZMapp is not really the story,” Whaley told the Hub. “The real story is about antibodies and how diverse they are. ZMapp shows the power of antibody-based technology, and that’s the exciting thing to us. They work; they are effective.”

Advertisement

Ebola, on the other hand, continues to be the story in West Africa and beyond. The disease has killed more than 6,300 people. Sierra Leone reported a big uptick, with nearly 400 new cases last week — that’s nearly three times as many as Guinea and Liberia combined. A volunteer American nurse who was exposed to the disease in Sierra Leone arrived at the National Institutes of Health facility in Bethesda last Thursday, signaling the disease will continue to hit home until it is stopped.

-30-
JOIN THE COMMUNITY, BECOME A MEMBER
Already a member? Sign in here
Connect with companies from the Technical.ly community
New call-to-action

Advertisement

Sysmex Inostics moves into bigger space near JHU medical campus

Frederick-based RoosterBio raises $15M Series B

Biotech manufacturing center near BWI will have space to produce spinal muscular atrophy treatment

SPONSORED

Baltimore

What Asymmetrik is doing to help lead healthcare’s digital transformation

Annapolis Junction, MD

Asymmetrik

FULL-STACK DEVELOPER

Apply Now
Annapolis Junction, MD

Asymmetrik

SOFTWARE ENGINEER

Apply Now
Annapolis Junction, MD

Asymmetrik

FRONT-END DEVELOPER

Apply Now

Paragon picks up more Md. manufacturing space in $18M deal with Novavax

Ricoh brings bioprinting to new business with Baltimore biotechnology company

A trio of Baltimore institutions are forming partnerships with Baxter International

SPONSORED

Baltimore

Verizon is looking for the brightest ideas on how to use its 5G technology

Baltimore

Agora Financial

Jr. Frontend Developer

Apply Now
Baltimore

Protenus

Training Specialist

Apply Now
Baltimore

Protenus

Senior Product Manager

Apply Now

Sign-up for daily news updates from Technical.ly Baltimore

Do NOT follow this link or you will be banned from the site!